Drug intelligence / Profile preview

INN-03

Development stage: Preclinical
Lead developer: Innox Pharma
Modality: Small Molecules

Overview

INN-03 is a small-molecule, broad-spectrum kinase inhibitor developed by Innox Pharma. It is specifically designed to target Class III receptor tyrosine kinases, with potent activity against Fms-like tyrosine kinase 3 (FLT3) and its internal tandem duplication (ITD) mutation. FLT3/ITD mutations are prevalent in acute myeloid leukemia (AML) and are associated with high relapse rates and poor clinical outcomes. By inhibiting these kinases, INN-03 disrupts critical signaling pathways that drive the uncontrolled proliferation and survival of malignant cells. The drug is currently in the preclinical stage of development, with potential therapeutic applications in hematological malignancies and solid tumors.

Targets

FLT3 (Fms related receptor tyrosine kinase 3)PDGFR (PDGFR family)

Beyond the preview

Go deeper on INN-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INN-03.

Explore the full profile